1. Home
  2. MLYS vs FAX Comparison

MLYS vs FAX Comparison

Compare MLYS & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • FAX
  • Stock Information
  • Founded
  • MLYS 2019
  • FAX 1986
  • Country
  • MLYS United States
  • FAX United States
  • Employees
  • MLYS N/A
  • FAX N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • FAX Investment Managers
  • Sector
  • MLYS Health Care
  • FAX Finance
  • Exchange
  • MLYS Nasdaq
  • FAX Nasdaq
  • Market Cap
  • MLYS 526.1M
  • FAX 629.1M
  • IPO Year
  • MLYS 2023
  • FAX N/A
  • Fundamental
  • Price
  • MLYS $10.46
  • FAX $15.62
  • Analyst Decision
  • MLYS Strong Buy
  • FAX
  • Analyst Count
  • MLYS 2
  • FAX 0
  • Target Price
  • MLYS $30.00
  • FAX N/A
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • FAX 833.6K
  • Earning Date
  • MLYS 03-20-2025
  • FAX 01-01-0001
  • Dividend Yield
  • MLYS N/A
  • FAX 12.09%
  • EPS Growth
  • MLYS N/A
  • FAX N/A
  • EPS
  • MLYS N/A
  • FAX N/A
  • Revenue
  • MLYS N/A
  • FAX N/A
  • Revenue This Year
  • MLYS N/A
  • FAX N/A
  • Revenue Next Year
  • MLYS N/A
  • FAX N/A
  • P/E Ratio
  • MLYS N/A
  • FAX N/A
  • Revenue Growth
  • MLYS N/A
  • FAX N/A
  • 52 Week Low
  • MLYS $8.58
  • FAX $2.33
  • 52 Week High
  • MLYS $16.91
  • FAX $2.84
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 51.57
  • FAX 59.01
  • Support Level
  • MLYS $9.81
  • FAX $15.40
  • Resistance Level
  • MLYS $10.79
  • FAX $15.57
  • Average True Range (ATR)
  • MLYS 0.62
  • FAX 0.15
  • MACD
  • MLYS 0.15
  • FAX 0.05
  • Stochastic Oscillator
  • MLYS 100.00
  • FAX 80.00

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities, and others.

Share on Social Networks: